Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.42 |
| ▸ | IDH1 | O75874 | 13/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8621250 | 0.78 | ANPEP (0.42) | CRBNIDH1GSK3BDDB1 | |
| SCHEMBL22509084 | 0.78 | ANPEP (0.42) | CRBNIDH1GSK3BDDB1 | |
| SCHEMBL29415789 | 0.78 | ANPEP (0.42) | CRBNIDH1GSK3BDDB1 | |
| SCHEMBL31729609 | 0.78 | GSK3B (0.42) | CRBNIDH1GSK3BRIPK1DDB1 | |
| SCHEMBL8622452 | 0.78 | GSK3B (0.42) | CRBNIDH1GSK3BRIPK1DDB1 | |
| SCHEMBL2882354 | 0.75 | CRBN (0.45) | CRBNIDH1GSK3B | |
| SCHEMBL30160057 | 0.74 | GSK3B (0.42) | CRBNIDH1GSK3BDDB1 | |
| SCHEMBL23532179 | 0.74 | CRBN (0.49) | CRBNIDH1RIPK1DDB1 | |
| SCHEMBL20073751 | 0.74 | IDH1 (0.43) | CRBNIDH1DDB1 | |
| SCHEMBL14893181 | 0.73 | OPRL1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | CRBN 3470/4885IDH1 3596/4885ADRA2A 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.